DOCSLIB.ORG

Haemochromatosis a Pietrangelo

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Haemochromatosis a Pietrangelo ii23 PAPER Gut: first published as 10.1136/gut.52.suppl_2.ii23 on 1 May 2003. Downloaded from Haemochromatosis A Pietrangelo ............................................................................................................................. Gut 2003;52(Suppl II):ii23–ii30 Iron is an important component of the Earth’s crust, but and associated to a mutation in the SLC11A3 its own chemistry greatly limits utilisation and also sets gene,10 coding for a main iron export protein in mammals, ferroportin/IREG/MTP-1. 11–13 the basis for its toxicity. The capacity of readily In the vast majority of cases around the world, exchanging electrons in aerobic conditions makes iron HC is attributable to mutations in the HFE essential for fundamental cell functions, such as DNA gene.14 However, it must be emphasised that while the presence of mutations in the HFE gene synthesis, transport of oxygen and electrons, and cell indicates the existence of the genetic form of HC, respiration. On the other hand, as humans have no the clinical diagnosis of HC is made when iron means to control iron excretion, excess iron, regardless overload is present (see later). Therefore, the identification of any one of the HFE mutations of the route of entry, accumulates in parenchymal (C282Y homozygosity or C282Y/H63D compound organs and threatens cell viability. In fact, a number of hererozigosity) is, by itself, insufficient for the disease states (that is, iron overload diseases) diagnosis of HC. Instead, the identification of the genetic abnormality provides evidence of suscepti- attributable to genetic or acquired factors are bility to developing the phenotype. The diagnosis pathogenetically linked to excess body iron stores and of HC, therefore, must be based on phenotype iron removal therapy is an effective lifesaving strategy in rather then genotype. As mentioned, mutations in other genes have been associated to HC, including such circumstances. SLC11A310 15 and transferrin receptor 2 (TfR2).16 .......................................................................... These mutations may be responsible for heredi- tary iron overload diseases non-HFE or act as modifiers genetic factors in HFE HC heterozy- DEFINITION gotes. All the three forms of HC described so far Haemochromatosis (HC)—synonymous with ge- are characterised by tissue iron overload, organ netic, hereditary, primary iron overload—is the disease and they require iron removal therapy as paradigm of a genetic disorder leading to body http://gut.bmj.com/ treatment. However, the form attributable to HFE, iron overload and multi-organ failure. HC is and apparently that attributable to TfR2 muta- attributable to inappropriately increased iron tions (although the latter has not been exten- absorption in which iron loading of parenchymal sively described clinically, yet) seem to share cells in the liver, pancreas, heart, and other organs common histopathological (predominant paren- impairs the function and damages the structure chymal iron overload) and clinical features. The of these organs.1 This condition is caused by form attributable to the SCL11A3 gene mutations inborn errors of iron metabolism. As shown in (see later) shows peculiar features. In view of on September 30, 2021 by guest. Protected copyright. figure 1, at least three genes may now be these findings the classification of HC has to be associated with a disease phenotype fulfilling this redefined (fig 1). definition, while a distinction should be made between HC and siderosis (that is, excess iron GENETICS, EPIDEMIOLOGY, AND accumulation in tissues) that indirectly results MOLECULAR PATHOGENESIS from other conditions that bring about iron over- HC is the most common inherited autosomal load (acquired iron overload) (fig 1). recessive disorder in the white population, affect- Von Recklinghausen, in 1889, first coined the ing about 1 in 200 of northern European term HC to indicate an iron storage disease with ancestry.14 In the original paper by Feder et al7 2 widespread tissue injury ; he was basically refer- most HC patients were homozygous for a single ring to the clinical syndrome of portal cirrhosis, base transition, resulting in the substitution of a diabetes mellitus, and bronze skin pigmentation, tyrosine for cysteine at position 282 (C282Y) of 3 described by Trousseau 24 years before. After the the unprocessed polypeptide. This mutation pre- identification of the inherited nature of HC by vents correct folding of HFE and, hence, assembly Sheldon,4 Simon and coauthors defined the β β with 2 microglobulin ( 2M) and presentation at incidence and genetic transmission of the disease the cell surface. The distribution of C282Y muta- ....................... that seemed to be linked to the HLA complex on tion coincides with the presence of the disease the short arm of chromosome 6 and mapped in Correspondence to: 56 and is in agreement with the theory of a Celtic or close proximity to the HLA-A locus. A corner- 14 Professor A Pietrangelo, north European origin of the mutation. The Department of Internal stone of HC genetics had been laid in 1996, when Medicine, University of the discovery of a gene candidate for HC was Modena and Reggio published.7 This gene, formerly named HLA-H (H ................................................. Emilia, 41100 Modena, for haemochromatosis), it was then redefined Italy; Abbreviations: HC, haemochromatosis; Tf, transferrin; HFE by the WHO Nomenclature Committee for TfR, transferrin receptor; UIBC, unsaturated iron binding pietrangelo.antonello@ 8 unimo.it Factors of the HLA system. Recently, an auto- capacity; HIC, hepatic iron concentration; HII, hepatic iron ....................... somal dominant form of HC has been described9 index www.gutjnl.com ii24 Pietrangelo 1 Primary iron overload Figure 1 Classification of iron overload diseases. A Haemochromatosis associated to mutations in the HFE gene: Gut: first published as 10.1136/gut.52.suppl_2.ii23 on 1 May 2003. Downloaded from C282Y homozygosity C282Y/H63D compound heterozygosity B Hereditary iron overload associated to mutations in the SLC11A3 gene (Ferroportin/MTP/IREG-1) C Hereditary iron overload associated to mutations in the Transferrin receptor 2 gene D Aceruloplasminaemia E Congenital atransferrinaemia F Others (unidentified genes) 1) Juvenile haemochromatosis 2) Neonatal haemochromatosis 2 Secondary iron overload A Dietary iron overload B Parental iron overload C Iron loading anaemias D Long term haemodialysis E Chronic liver disease Hepatitis C Alcoholic cirrhosis, especially when advanced Non-alcoholic steatohepatitis F Porphyria cutanea tarda G Post-portacaval shunting H Dysmetabolic iron overload syndrome 3 Miscellaneous Iron overload in sub-Sahara Africa percentages of C282Y homozigosity are >90% in the UK and membrane, but is required for HFE to be transported to Tf Brittany with a decreasing gradient northern to southern positive endosomes and for regulation of intracellular iron Europe, with the lowest percentage in Italy (64%) and Greece homeostasis in cultured cells.25 This suggests that the biologi- (30%). Indeed, HC is an example of a founder (the Celtic) cal effect of HFE on TfR may be exerted in the endosomal http://gut.bmj.com/ effect, combined with a strong positive selection of the C282Y compartment where iron is released from TfR-Tf complex and allele, which may confer the ability to absorb more iron and not necessarily at the cell surface. At the tissue level, HFE to survive better in ancient times, when iron deficiency was appears to be preferentially expressed in duodenal crypt cells extremely common. and Kupffer cells of the liver, mainly in the perinuclear A second mutation resulting in the substitution of an compartment.26 27 aspartic acid for histidine at position 63 (H63D) was found in Iron absorption is inappropriate to body iron stores in HC, a number of patients who carried only one copy of the C282Y and steadily increases from birth despite expanding iron on September 30, 2021 by guest. Protected copyright. 7 mutation. The H63D mutation has a worldwide distribution deposits28 (fig2A and B). Typically, in HC subjects there is a 14 with the highest frequency among Basques. This mutation positive iron balance of 1 mg to 2 mg of iron daily that during may have a clinical significance only in cooperation with other childhood and adolescence in men and in menstruated genetic or environmental factors (for example, viral hepatitis, women does not cause marked iron accumulation because of thalassaemia, porphyrias etc). A considerably smaller pro- high growth demands and iron losses, respectively. After- portion of patients are compound heterozygotes for the two wards, iron overload in the liver, pancreas, heart, and joints, mutations (genotype HD/CY). A third substitution of cysteine leads to parenchymal cell damage and organ disease. In view for serine at amino acid position 65 (S65C), has been of the available data, any proposed model of HFE function in implicated in a mild form of HC,17 whereas the role of other iron metabolism has to consider (a) the biochemical evidence rare mutations found in subjects H63D or C282Y heterozy- gotes, is unclear.18 (that is, HFE interacts with TfR1), (b) the pattern of The human HFE protein is closely related to the major his- expression of TfR1 and HFE in vivo, and (c) the phenotype of tocompatibility complex (MHC) class I molecules. The C282Y human HC. α At the biochemical level, data from several tissue culture mutation disrupts a critical disulfide bond in the 3 domain of the HFE
Load more

Recommended publications
  • Syllabus METAL ION EXCESS TOXICITY
    Syllabus Metalionexcesstoxicity-Feexcesstoxicity-Africansiderosis,hemosiderosis, hemochromatosis(bronzediabetes)anddetoxification.Cuexcesstoxicity:Wilson’sdisease andtreatment. Heavymetaliontoxicity:Hg,Pb,Cd,Astoxiceffects–mechanismoftoxiceffects.Heavy metaltoxicitytreatment-chelationtherapy:chelatingagentsforHg,Pb,Cd,Astoxicity. Metalcomplexesasdrugs:cis-plainasanticanceragent:mechanismofactionandside effects;goldcomplexesasantiarthriticdrugs-chrysotherapy.Metalcomplexesindiagnosis- Gdcomplexesinmagneticresonanceimaging(MRI). METALIONEXCESSTOXICITY Ironexcesstoxicity ü ItisduetoaccidentalintakeofFeSO4tabletscausingerosionofthegastrointestinal tract. ü Hemochomatosisisageneticdisorder,depositionofironoccursinvitalorganslike liver,spleen,pancreas,skinetc.Itleadstobronzepigmentationontheskiniscalled bronzediabetes. ü Siderosis(depositionofFeOdustinthelungs)isassociatedwithexcessofiron. ü AfricansiderosisisanironoverloaddisorderfirstobservedamongpeopleofSouthern AfricaandCentralAfrica.Dietaryironoverloadistheconsumptionoflargeamount ofhome-brewedbeerwithhighamountofironcontentinit. Detoxification : Siderophore desferrioxamine is a chelating antidote used for Fe removal Coppertoxicity Copper is a principal component of several metalloproteins and some naturally occurring pigments.Ahealthyadultpossessescopperbetween200to300mgandthehighestamountis concentratedin the locus of brain. Wilson’sdiseaseand Menkes’ kinky hair syndromeare associatedwithageneticdisorderinthemetabolismofcopper. Wilson’sdisease ü In Wilson'sdisease,the copper-content
    [Show full text]
  • Chelation Therapy
    Corporate Medical Policy Chelation Therapy File Name: chelation_therapy Origination: 12/1995 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine (not Food and Drug Administration [FDA] approved) is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer’s disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer’s disease, they promote the solubilization and clearance of β-amyloid protein by binding to its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer’s disease. However, no MPACs have received FDA approval for treating Alzheimer’s disease. Chelation therapy has also been investigated as a treatment for other indications including atherosclerosis and autism spectrum disorder.
    [Show full text]
  • Nr 1. Each Patient Suffering from Acute Coronary Syndrome Must Be Treated With
    SED - 3 - VERSION I February 2009 Nr 1. Each patient suffering from acute coronary syndrome must be treated with: A. Acetylsalicylic acid (ASA). B. ASA or clopidogrel. C. ASA and clopidogrel. D. depending on the type of myocardial infarction – ASA and clopidogrel or ASA only. E. depending on the mode of treatment (invasive vs noninvasive) – ASA and clopidogrel or ASA only. Nr 2. A patient in the class IV of Killip-Kimball classification has: A. pulmonary oedema. B. cardiogenic shock. C. blood retention (haemostasis) below the level of inferior angles of scapulae. D. no signs of heart insufficiency. E. chronic heart insufficiency, previously at least in NYHA class III. Nr 3. Schőnlein-Henoch purpura is a vasculitis that: A. is characterized by nephritic syndrome with cANCA antibodies. B. may present as rapidly progressive glomerulonephritis. C. is often accompanied by granulomas in the lungs. D. is typically treated by a surgical excision of granuloma. E. is typically treated by nephrectomy of the kidney with granulomas. Nr 4. Which of the below given drugs can cause hyperkalemia? 1) angiotensin converting enzyme inhibitors. 2) loop diuretics. 3) aldosterone antagonist. 4) thiazide. 5) indapamide. The correct answer is: A. 1,3. B. 1,2,3. C. 1,3,4. D. 1,3,5. E. all of the above. Nr 5. Which of the below is an absolute contraindication to thrombolytic therapy in acute myocardial infarction: A. age above 75. B. suspected dissecting aortic aneurysm. C. past cerebral stroke 2 years ago. D. high blood pressure >175/110 mmHg. E. invasive cardiology unit available on duty, which can be reached within 90 minutes.
    [Show full text]
  • Revisiting Hemochromatosis: Genetic Vs
    731 Review Article on Unresolved Basis Issues in Hepatology Page 1 of 16 Revisiting hemochromatosis: genetic vs. phenotypic manifestations Gregory J. Anderson1^, Edouard Bardou-Jacquet2 1Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute and School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia; 2Liver Disease Department, University of Rennes and French Reference Center for Hemochromatosis and Iron Metabolism Disease, Rennes, France Contributions: (I) Conception and design: Both authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors. Correspondence to: Gregory J. Anderson. Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland 4006, Australia. Email: [email protected]. Abstract: Iron overload disorders represent an important class of human diseases. Of the primary iron overload conditions, by far the most common and best studied is HFE-related hemochromatosis, which results from homozygosity for a mutation leading to the C282Y substitution in the HFE protein. This disease is characterized by reduced expression of the iron-regulatory hormone hepcidin, leading to increased dietary iron absorption and iron deposition in multiple tissues including the liver, pancreas, joints, heart and pituitary. The phenotype of HFE-related hemochromatosis is quite variable, with some individuals showing little or no evidence of increased body iron, yet others showing severe iron loading, tissue damage and clinical sequelae. The majority of genetically predisposed individuals show at least some evidence of iron loading (increased transferrin saturation and serum ferritin), but a minority show clinical symptoms and severe consequences are rare.
    [Show full text]
  • EASL Clinical Practice Guidelines: Wilson's Disease
    Clinical Practice Guidelines EASL Clinical Practice Guidelines: Wilson’s disease ⇑ European Association for the Study of the Liver Summary with acute liver failure. Wilson’s disease is not just a disease of children and young adults, but may present at any age [5]. This Clinical Practice Guideline (CPG) has been developed to Wilson’s disease is a genetic disorder that is found worldwide. assist physicians and other healthcare providers in the diagnosis Wilson’s disease is recognized to be more common than previ- and management of patients with Wilson’s disease. The goal is to ously thought, with a gene frequency of 1 in 90–150 and an inci- describe a number of generally accepted approaches for diagno- dence (based on adults presenting with neurologic symptoms sis, prevention, and treatment of Wilson’s disease. Recommenda- [6]) that may be as high as 1 in 30,000 [7]. More than 500 distinct tions are based on a systematic literature review in the Medline mutations have been described in the Wilson gene, from which (PubMed version), Embase (Dialog version), and the Cochrane 380 have a confirmed role in the pathogenesis of the disease [8]. Library databases using entries from 1966 to 2011. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system used in other EASL CPGs was used and set against the somewhat different grading system used in the Clinical presentation AASLD guidelines (Table 1A and B). Unfortunately, there is not a single randomized controlled trial conducted in Wilson’s dis- The most common presentations are with liver disease or neuro- ease which has an optimal design.
    [Show full text]
  • Diagnosis and Treatment of Wilson Disease: an Update
    AASLD PRACTICE GUIDELINES Diagnosis and Treatment of Wilson Disease: An Update Eve A. Roberts1 and Michael L. Schilsky2 This guideline has been approved by the American Asso- efit versus risk) and level (assessing strength or certainty) ciation for the Study of Liver Diseases (AASLD) and rep- of evidence to be assigned and reported with each recom- resents the position of the association. mendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Prac- Preamble tice Guidelines3,4). These recommendations provide a data-supported ap- proach to the diagnosis and treatment of patients with Introduction Wilson disease. They are based on the following: (1) for- Copper is an essential metal that is an important cofac- mal review and analysis of the recently-published world tor for many proteins. The average diet provides substan- literature on the topic including Medline search; (2) tial amounts of copper, typically 2-5 mg/day; the American College of Physicians Manual for Assessing recommended intake is 0.9 mg/day. Most dietary copper 1 Health Practices and Designing Practice Guidelines ; (3) ends up being excreted. Copper is absorbed by entero- guideline policies, including the AASLD Policy on the cytes mainly in the duodenum and proximal small intes- Development and Use of Practice Guidelines and the tine and transported in the portal circulation in American Gastroenterological Association Policy State- association with albumin and the amino acid histidine to 2 ment on Guidelines ; (4) the experience of the authors in the liver, where it is avidly removed from the circulation. the specified topic.
    [Show full text]
  • Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros Bicornis)
    animals Review Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros bicornis) Kathleen E. Sullivan, Natalie D. Mylniczenko , Steven E. Nelson Jr. , Brandy Coffin and Shana R. Lavin * Disney’s Animal Kingdom®, Animals, Science and Environment, Bay Lake, FL 32830, USA; [email protected] (K.E.S.); [email protected] (N.D.M.); [email protected] (S.E.N.J.); Brandy.Coffi[email protected] (B.C.) * Correspondence: [email protected]; Tel.: +1-407-938-1572 Received: 29 September 2020; Accepted: 26 October 2020; Published: 29 October 2020 Simple Summary: Black rhinoceros under human care are predisposed to Iron Overload Disorder that is unlike the hereditary condition seen in humans. We aim to address the black rhino caretaker community at multiple perspectives (keeper, curator, veterinarian, nutritionist, veterinary technician, and researcher) to describe approaches to Iron Overload Disorder in black rhinos and share learnings. This report includes sections on (1) background on how iron functions in comparative species and how Iron Overload Disorder appears to work in black rhinos, (2) practical recommendations for known diagnostics, (3) a brief review of current investigations on inflammatory and other potential biomarkers, (4) nutrition knowledge and advice as prevention, and (5) an overview of treatment options including information on chelation and details on performing large volume voluntary phlebotomy. The aim is to use evidence to support the successful management of this disorder to ensure optimal animal health, welfare, and longevity for a sustainable black rhinoceros population. Abstract: Critically endangered black rhinoceros (BR) under human care are predisposed to non-hemochromatosis Iron Overload Disorder (IOD).
    [Show full text]
  • Front Matter (PDF)
    HIGH RATE OF SUCCESS IN AN NIH-SPONSORED STUDY of hypertensive patients- the highest 83% withpercentageNORVASC#{174}- remained(amlodipineon initialbesylate)therapy after 4 years; nearly all patients were on the 5-mg starting dose’ LOW RATE OF DISCONTINUATION NY J50,oof(n=patients1730) discontinuedin placebo-controlledtherapy duestudiesto adverse effects2 PROVEN SAFETY No negative inotropic effects at clinical doses in hemodynamic studies2* No clinically significant effect on cardiac conduction or heart rate2 * Similar hemodynamic findings, however, have been observed with agents possessing significant negative inotropic effects. 5-mg and 10-mg tablets Once-Daily (amlodipinebesylate) EFFICACY AND SAFETY THAT’S EASY TO LIVE WITH Brief Summary NORVASC (amtodlpfne besylate) Tablets For Oral Use CONTRAINDICATIONS: NORVASC is conlraindicaled in palients wilh known sensitivity to amlodipine In hypertension WARNINGS: Increased Angina and/or Myocardlal Infarction: Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed documented increased frequency, duration and/sr severity of angina or acute myscardiat infarction on starting calcium channel blocker therapy or atthe time of dosage increase The mechanism of this effect has not been elucidated. PRECAUTIONS: General: Since the vasodilation induced by NORVASC is gradual in onset, acute hypvtension has rarely been reported after oral administration of NORVASC. Nonetheless, caution should be evercised when admin- or angina,convenient istering NORVASC as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. Use In Patients wIth CongestIve Heart FaIlure: In general, calcium channel blockers should be used with caution in patients with heart failure. NORVASC (5-10 mg per day) has been studied in a placebo-controlled trial of 1153 patients with NYHA Class Ill or IV heart failure vn stable doses of ACE inhibitor, digoxin.
    [Show full text]
  • Evaluating and Treating the Kidneys
    16_Nephrology.qxd 8/23/2005 10:41 AM Page 451 CHAPTER 16 Evaluating and Treating the Kidneys M. SCOTT ECHOLS, DVM, D ipl ABVP-A vian Renal diseases and their various classifications are well documented in the avian literature. The precise patho- genesis of avian renal disease, however, is not nearly as well described as it is in mammals. Renal disease has been shown to be fairly common in avian species. In studied poultry, as much as 29.6% of all disease condi- tions had abnormal pathology associated with or attrib- utable to renal disorders.20,214,251 Amyloidosis, urate nephrosis and gout were the most common diseases associated with mortality in a 4-year retrospective study conducted at a waterfowl park in Ontario, Canada.210 Thirty-seven percent of all avian cases presenting with renal tissue for histopathological examination, included over a 15-month period at the Schubot Exotic Bird Health Center, had one or more histologically identified kidney lesions.187 Nine of 75 pheasants (Phasianus colchicus) died with nephritis, one or both ureters impacted, and visceral gout in another comprehensive study on avian mortality.186 These case reports and retro- spective studies support the conclusion that renal dis- eases are relatively common and are clinically significant in multiple avian species. When compared to mammalian counterparts, the avian urogenital system has many structural and functional differences, which have been described previously.77,90,118,181,187,227 Differences including gross anatomy, renal portal blood flow and protein waste elimination should be considered when reviewing this chapter, as findings obtained from mammalian studies may not necessarily be applicable to birds.
    [Show full text]
  • Cardiac Impairment Due to Hypocalcemia in a Multitransfused Patient with Thalassemia Major S Ansari, a Kiumarsi, T Rostami
    The Internet Journal of Hematology ISPUB.COM Volume 10 Number 1 Cardiac Impairment Due To Hypocalcemia In A Multitransfused Patient With Thalassemia Major S Ansari, A Kiumarsi, T Rostami Citation S Ansari, A Kiumarsi, T Rostami. Cardiac Impairment Due To Hypocalcemia In A Multitransfused Patient With Thalassemia Major. The Internet Journal of Hematology. 2014 Volume 10 Number 1. Abstract We report a case of a 16-year-old Iranian girl with transfusion-dependent thalassemia major who presented with chest pain. Laboratory investigations showed marked hypocalcemia, hypomagnesaemia, hyperphosphatemia, and an extremely low vitamin D3 level. She had a low parathyroid hormone (PTH) level. She was refractory to calcium and magnesium supplementation. However, she responded to oral cacitriol. She was diagnosed to have hypoparathyroidism most likely due to iron overload due to multitransfusions and vitamin D3 deficiency. Vitamin D3 deficiency most likely was independent of iron overload. Cardiomyopathy in this patient could have been secondary to iron overload and/or hypocalcemia. Hypocalcemia could have been due to hypoparathyroidism and/or the low vitamin D3 level. Her response to calcitriol but not to calcium and magnesium supplementation suggests that the hypocalcemia was due to hypoparathyroidism and/or vitamin D3 deficiency. The response to calcitriol also indicates that iron overload was not responsible since cardiac impairment due to iron overload would be refractory to calcitriol treatment. Cardiac failure in multitransfused patients is usually ascribed to hemosiderosis. This case demonstrates that hypocalcemia related to vitamin D3 insufficiency also can cause myocardial dysfunction. Patients with thalassemia minor should be periodically screened for calcium and vitamin D3 levels to avoid complications secondary to hypocalcemia.
    [Show full text]
  • Nutrition Journal of Parenteral and Enteral
    Journal of Parenteral and Enteral Nutrition http://pen.sagepub.com/ Micronutrient Supplementation in Adult Nutrition Therapy: Practical Considerations Krishnan Sriram and Vassyl A. Lonchyna JPEN J Parenter Enteral Nutr 2009 33: 548 originally published online 19 May 2009 DOI: 10.1177/0148607108328470 The online version of this article can be found at: http://pen.sagepub.com/content/33/5/548 Published by: http://www.sagepublications.com On behalf of: The American Society for Parenteral & Enteral Nutrition Additional services and information for Journal of Parenteral and Enteral Nutrition can be found at: Email Alerts: http://pen.sagepub.com/cgi/alerts Subscriptions: http://pen.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav >> Version of Record - Aug 27, 2009 OnlineFirst Version of Record - May 19, 2009 What is This? Downloaded from pen.sagepub.com by Karrie Derenski on April 1, 2013 Review Journal of Parenteral and Enteral Nutrition Volume 33 Number 5 September/October 2009 548-562 Micronutrient Supplementation in © 2009 American Society for Parenteral and Enteral Nutrition 10.1177/0148607108328470 Adult Nutrition Therapy: http://jpen.sagepub.com hosted at Practical Considerations http://online.sagepub.com Krishnan Sriram, MD, FRCS(C) FACS1; and Vassyl A. Lonchyna, MD, FACS2 Financial disclosure: none declared. Preexisting micronutrient (vitamins and trace elements) defi- for selenium (Se) and zinc (Zn). In practice, a multivitamin ciencies are often present in hospitalized patients. Deficiencies preparation and a multiple trace element admixture (containing occur due to inadequate or inappropriate administration, Zn, Se, copper, chromium, and manganese) are added to par- increased or altered requirements, and increased losses, affect- enteral nutrition formulations.
    [Show full text]
  • Case Report Endocrine Societies Hypoparathyroidism in a Case of Transfusion Dependent Thalassemia
    Journal of the ASEAN Federation of Case Report Endocrine Societies Hypoparathyroidism in a Case of Transfusion Dependent Thalassemia Anirban Majumder1 and Sagar Basu2 1Endocrinology Department, KPC Medical College, West Bengal University of Health Sciences, Kolkata, India 2Neurology Department, KPC Medical College, West Bengal University of Health Sciences, Kolkata, India Abstract Repeated blood transfusions in transfusion dependent thalassemia (TDT) leads to iron overload-related endocrine complications. Hypoparathyroidism (HPT) with severe signs of hypocalcemia is a recognized complication among these patients. A 14-year-old thalassaemic boy, on regular transfusion and on anticonvulsant therapy with a presumptive diagnosis of epilepsy for the last 1 year, was admitted with high fever and severe muscle cramps with positive Trousseau’s sign. He was diagnosed as a case of primary HPT and magnesium deficiency on the basis of low serum calcium, high phosphate, normal alkaline phosphates, very low intact parathyroid hormone (iPTH), normal serum vitamin D and very low serum magnesium level. His calcium, magnesium and phosphate level normalised following treatment with intravenous magnesium and calcium. His iPTH improved but remained at low normal. He was discharged from hospital with oral calcium, calcitriol, and magnesium supplementation. The anticonvulsant (Phenobarbitone) was successfully withdrawn gradually over the next six months without any recurrence of seizure in the subsequent 3 years of follow up. Acquired HPT (apparently from hemosiderosis) is a common cause of hypocalcemia; and magnesium depletion further complicated the situation leading to severe hypocalcemia with recurrent episodes of convulsion. Magnesium replacement improved the parathyroid hormone (PTH) value proving its role in acquired HPT. Very high phosphate level on admission and poor PTH response with respect to the low serum calcium, indicates intrinsic parathyroid pathology.
    [Show full text]